维普中文期刊产品整合服务

Single-use duodenoscopes for the prevention of endoscopic retrograde cholangiopancreatography -related cross-infection – from bench studies to clinical evidence

查看全文 作  者:Andrea [1]Lisotti;Pietro [1]Fusaroli;Bertrand [2]Napoleon;Anna [1]Cominardi;Rocco Maurizio [3]Zagari 高影响力作者 机构地区:[1]Gastroenterology Unit,Hospital of Imola,University of Bologna,Imola 40026,BO,Italy;[2]Gastroenterology Unit,Hôpital privéJean Mermoz-Ramsay Générale de Santé,Lyon 69008,FR,France;[3]Dipertimento Di Scienze Mediche e Chirurgiche,Universitàdi Bologna,Policlinico San Orsola Malpighi,Bologna 40138,Italy高影响力机构 出  处:《World Journal of Methodology》索引2022年第12卷第3期,共10页高影响力期刊 摘  要:BACKGROUND Several strategies have been implemented to reduce or abolish the life-threatening risk of endoscopic retrograde cholangiopancreatography(ERCP)-related multidrug-resistant infections due to duodenoscopes contaminations;among those strategies,serial microbiologic tests,thorough reprocessing schedules,and use of removable scope cap have been adopted,but the potential cross-infection risk was not eliminated.AIM To review available evidence in the field of single-use duodenoscopes(SUD)use for ERCP.METHODS An overview on ongoing clinical studies was also performed to delineate which data will become available in the next future.RESULTS One bench comparative study and four clinical trials performed with EXALT model-D(Boston Scientific Corp.,United States)have been identified.Of them,one is a randomized controlled trial,while the other three studies are prospective single-arm,cross-over studies.Pooled technical success rate(4 studies,368 patients)was 92.9%[95%confidence interval(CI):89.9-95.5;I2:11.8%].Pooled serious adverse event(4 studies,381 patients)rate was 5.9%[3.7%-8.5%;I2:0.0%].CONCLUSION Although few clinical trials are available,evidence is concordant in identifying an absolute feasibility and safety and feasibility for SUD use for ERCP.The expertise and quality of evidence in this field are going to be improved by further large clinical trials;data on cost-effectiveness and environmental impact will be needed for a worldwide spread of SUD use for ERCP. 关 键 词:MULTIDRUG Resistance CONTAMINATION INFECTION REPROCESSING Guidelines
相关文献

参考文献(29)

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费